MS-553 not checked

MingSight Pharmaceuticals, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema, Diabetic Retinopathy
Main trialPhase 1/2
“A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma”In the company’s words, NCT06979076 on ClinicalTrials.gov

Other drugs for CLL (Chronic Lymphocytic Leukemia)

All 64 drugs for CLL (Chronic Lymphocytic Leukemia)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting Sep 2028 A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
Phase 1Recruiting 30 Oct 2026 MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Phase 1/2Terminated 28 Nov 2023 A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Phase 1/2Terminated 28 Nov 2023 A Study Of The Selective PKC-β Inhibitor MS- 553
Phase 1/2Terminated 28 Nov 2023 A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MS-553

Following is part of Solo: you see every change to MS-553 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in